Comparison of Olopatadin and Ketotifen in the Treatment of Allergic Conjunctivitis
Main Article Content
Keywords
Ketotifen, Conjunctivitis, Allergic
Abstract
Objective: to compare the efficacy of olopatadine 0.1 % and ketotifen 0.025 % ophthalmic solutions in the treatment of allergic conjunctivitis.
Methods: forty patients with allergic conjunctivitis were included in the study, they were randomized in two groups: G-I (n = 20) olopatadine 0.1 % and G-II (n = 20) ketotifen 0.025 %, both receiving one drop every 12 hours. We evaluated itching, burning, tearing, redness and chemosis previously and 30 minutes, one, two and four week after.
Results: age G-I was 19.7 ± 6.7 years; G-II, 21.05 ± 8.3 years. When evaluating itching, olopatadine had a significant improvement at 30 minutes and after one week (p < 0.05). In the following weeks, the results were similar in both groups. Olopatadine showed significant improvement in burning at 30 minutes, one and two week (p < 0.05). Tearing significantly decreased at 30 minutes with olopatadine (p < 0.05). There was no difference in redness or chemosis improvement in both groups.
Conclusions: in this study, olopatadine 0.1 % was more effective than topical ketotifen 0.025 % in improving itching, tearing and burning in allergic conjunctivitis patients.
References
Toribio E. Conjuntivitis alérgica. Alerg Asma Inmunol Pediatr 2001;10(1):15-19.
Aguilar AJ, Berra A. Alergia ocular. Médico Oftalmólogo [revista en internet] 2001;14(4):15-17. Disponible en http://www.oftalmologos.org.ar/mo/mo144-1.html#alergia
Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol 2000;106(6):1019-1032.
Kidd M, McKenzie S, Steven I, Cooper C, Lanz R. Efficacy and safety of ketotifen eye drops in treatment of seasonal allergic conjunctivitis. Br J Ophthalmol 2003;87(10):1206-1211.
Mösges R. The increasing prevalence of allergy a challenge for physician. Clin Exp Allergy 2002; 2(1):13-17.
Vázquez NF, Salas RE, Mogica MJ, Beltrán GF. Prevalencia y factores de riesgo para la conjuntivitis alérgica en población infantil. Estudio comparativo efectuado en dos comunidades. Rev Alerg Mex 2002;49(2):33-41.
Escallón BF. Posibilidades terapéuticas en la conjuntivitis de origen alérgico. Franja Ocular 1999;1(5):26-27.
Yanni JN, Sharif NA, Gamache DA, Millar ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol Scand Suppl 1999;77(228):33-37.
Merayo J, Montero J, Sainz-de la Maza M, Fuster E, Lladanosa A. Efectividad e impacto en la calidad de vida del colirio de ketotifeno: resultados del estudio ZETA, en pacientes con conjuntivitis alérgica estacional. Arch Soc Esp Oftalmol [revista en internet] 2003;78(8):433-442. Disponible en http://scielo.isciii.es/scielo.php?script = sci _arttext&
Abelson M, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic agent with dual activity. Am J Ophthalmol 1998;125(6):797-804.
Ciprandi G, Turner D, Gross R. Double masked randomized, parallel-group study comparing olopatadine 0.1 % ophthalmic solution with cromolyn sodium 2 % and levocabastine 0.05 % ophthalmic preparations in children with seasonal allergic conjunctivitis. Curr Ther Res Clin Exp 2004;65(2): 186-199.
Abelson MB, Chapin MJ, Kapik BM, Shams NB. Efficacy of ketotifen fumarate 0.025 % ophthalmic solution compared with placebo in conjunctival allergen challenge model. Arch Ophthalmol 2003; 121(5):626-630.
Greiner J, Mundorft T, Dubiner H, Lonsdale J, Casey R, Parver L, et al. Efficacy and safety of ketotifen fumarate 0.025 % in conjunctival antigen challenge model of ocular allergic conjunctivitis. Am J Ophthalmol 2003;136(6):1097-1105.
Campuzano M, Juárez E, López P, Penagos P, Ordaz F. Alergenos y factores de riesgo en pacientes pediátricos con conjuntivitis alérgica estacional. Rev Alergia Mex 2002;49(4):105-111.
Gaytan Melicoff JA, Baca-Lozada O, Velasco-Ramos R, Viggiano-Austria D. Comparación entre el suero autólogo, clorhidrato de olopatadina y fumarato de ketotifeno en el manejo de la conjuntivitis alérgica. Rev Mex Oftalmol 2005;79(1): 25-31.
Bielory L, Lien K, Bigelsen S. Efficacy and tolerability of newer antihistamines in treatment of allergic conjunctivitis. Drugs 2005;65(2):215-228.
Abelson M, Ferzola N, McWhirter C, Crampton H. Efficacy and safety of single and multiple-dose ketotifen fumarate 0.025 % ophthalmic solution in a pediatric population. Pediatr Allergy Immunol 2004;15(6):551-557.
Woerly G, Loiseau S, Loyens M, Schoch C, Capron M. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases. Allergy 2003;58(5):397-406.
Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1 % olopatadine hydrochloride versus 0.05 % ketotifen fumarate. Acta Ophthalmol Scand Suppl 2000;78(230):52-55.
Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025 % and olopatadine HCl 0.1 % ophthalmic solutions in seasonal allergic conjunctivities: a 30 day, randomized, double-masked, artificial tear substitute-controlled trial. Clinical therapeutics 2005;27(9): 1392-1402.
Berdy GJ, Spangler D, Bensch G, Berdy SS, Brussati RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1 % ophthalmic solution and ketotifen fumarate 0.025 % ophthalmic solution in conjunctival antigen challenge model. Clin Ther 2000;22(7):826-833.
Ono SJ Abelson MB. Allergic conjunctivitis: update con pathophysiology and prospect for future treatment. J Allergy Clin Inmunol 2005;115(1): 118-122.
Katelaris C, Ciprandi G, Missoten L, Turner FD, Bertin B, Berdeaux G, et al. A comparison of efficacy and tolerability of olopatadine hydrochloride 0.1 % ophthalmic solution and cromolyn sodium 2 % ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002;24(10):1561-1575.
Brodsky M. Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1 % therapy. Acta Ophthalmol Scand Suppl 2000;78(230):56-59.
Artal MN, Luna JD, Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1 % versus ketotifen fumarate 0.05 %. Acta Ophthalmol Scand Suppl 2000;78(230):64-65.
Abelson M, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1 % ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjuntivitis and rhinoconjunctivitis. Clin Ther 2003;25(3):931-947.